Baltimore, MD (October 1, 2014) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced that they have been selected as an Innovator Presenter at the 6th Annual Partnering for Cures meeting to be held in New York, NY, on November 16 – 18, 2014.
This meeting is convened by FasterCures, a centre of the Milken Institute, which is focused on speeding up the process of getting new medical solutions from labs to patients. Innovator Presenters are organizations recognized by FasterCures for their innovative, cross-sector research collaboration models.
For further information about NTAP and its programs, please visit NTAP
About NTAP
Neurofibromatosis Therapeutic Acceleration Program (NTAP) is a privately funded non-profit organization dedicated solely to developing effective treatments for patients with neurofibromatosis type 1-associated plexiform neurofibromas. Its programs span exploratory research through clinical trials and marketing approval, to ensure patients benefit from innovative research as quickly as possible.
About plexiform neurofibormas
Plexiform neurofibormas (pNFs) are the most common type of tumor in individuals with neuofibromatosis type 1 (NF1), a genetic disorder characterized by distinctive skin abnormalities and a high number of non-cancerous tumors that grow throughout the body. pNFs can occur in any part of the body and can grow throughout a person’s lifetime, often becoming disfiguring, disabling or deadly. There are currently no known therapies that are effective at stopping or reversing their growth or their impact on the lives of patients with NF1.